EAU 2013 - Programme Book - YouMed

Sunday, 17 March
Sponsored Session
17.45 - 19.15 Focal therapy in localised prostate cancer
Amber Hall 7-8 - Level S2
Symposium
Chair: C. Stief, Munich (DE)
Guest of honour
P. Palma, Campinas (BR)
Welcome and opening remarks
C. Stief, Munich (DE)
Mechanism of action
H.G. Van Der Poel, Amsterdam (NL)
Phase II studies meta-analysis (safety, efficacy and quality of life)
J. Rassweiler, Heilbronn (DE)
4 years results of the phase II studies/Retreatments (no loss of chance)
E. Barret, Paris (FR)
European phase III trial update
A.R. Azzouzi, Angers (FR)
Focal therapy for prostate cancer ‘a new paradigm’
E. Solsona, Valencia (ES)
Questions/answers and panel discussion
Aims and objectives
The current choice for men with localized prostate cancer is either radical therapy or active surveillance.
In the last decade a new therapeutic approach, aiming at the focal treatment of the cancer, has gained
increasing use.
TOOKAD ® Soluble Vascular Targeted Photodynamic (VTP) therapy is a novel focal therapeutic modality that
enables the occlusion of the entire tumor vasculature in a few minutes of treatment, which results in the
necrosis of the prostatic tumor.
During this symposium, participants will hear new information regarding this new molecule: TOOKAD®
Soluble, gain a good understanding of the mechanism of action, efficacy, safety and tolerability of the
product, and will receive updated information on the ongoing European Phase III study.
Sponsored by STEBA BIOTECH
EAU Milan 2013
417
Sponsored Sessions